Cat. No. 5037
Chemical Name: 5-(Aminomethyl)-1-[(2S)-5,7-difluor
Biological ActivityPotent and selective dopamine β-hydroxylase (DBH) inhibitor (IC50 = 9 nM) . Selective for DBH over 12 other enzymes. Decreases noradrenaline and increases dopamine levels in tissues and plasma in hypertensive rats. Prevents progressive left ventricular dysfunction in an in vivo heart failure model. Also potentiates the stimulus effects of cocaine without producing cocaine-like effects in rats. Orally bioavailable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Manvich et al (2013) Dopamine β-hydroxylase inhibitors enhance the discriminative stimulus effects of cocaine in rats. J.Pharmacol.Exp.Ther. 347 564. PMID: 24068832.
Sabbah et al (2000) Effects of dopamine β-hydroxylase inhibition with nepicastat on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Circulation 102 1990. PMID: 11034950.
Stanley et al (1997) Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase. Br.J.Pharmacol. 121 1803. PMID: 9283721.
If you know of a relevant reference for Nepicastat hydrochloride please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Nepicastat hydrochloride from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Nepicastat hydrochloride, supplier, dopamine, beta-hydroxylase, inhibitors, inhibits, β, B-hydroxylase, DBH, noradrenaline, norepinephrine, potent, selective, orally, bioavailable, DBH, Tocris Bioscience, Hydroxylase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Fluorometric CYP450 substrateGaleterone
CYP17 inhibitor; also androgen receptor antagonistPF 04449613
Potent PDE9 inhibitor; brain penetrant
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.